Full Press Release Details
Doron Besser is the CEO of ENvue Medical and NanoVibronix (Nasdaq: NAOV), overseeing the integration of the two divisions: electromagnetic navigation for enteral feeding (ENvue) and non-invasive therapeutic devices for pain and urology (NanoVibronix).
Doron is continuing the advancement and commercialization of ENvue navigation system for enteral feeding, leading global strategy, clinical education, commercialization in the U.S. and ROW, and expansion into new applications including pediatrics and vascular access.
Prior to managing both divisions, Doron co-founded and managed ENvizion Medical and Swing Medical, a private equity investment fund. Doron guided ENvizion Medical from concept to FDA clearance, built U.S. clinical adoption, and launched the ENvue system into hospitals as a next-generation navigation platform.
Doron also co-founded and led NutriSeal, a company focused on preventing nasoenteral-induced gastric reflux and ventilator-associated pneumonia (VAP). Prior to NutriSeal, Doron served as CEO of Angioslide Ltd., a company specializing in innovative, cost effective angioplasty products. Doron guided the company through its infancy stages, which included complicated animal and human trials, to FDA clearance, CE approval and initial market penetration in Europe and the US. Doron also served as VP of Clinical and Marketing and VP of Business Development at super Dimension, a leader in minimally-invasive pulmonology devices. Doron helped lead super Dimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for ~$300 million.
As a seasoned entrepreneur, Doron specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales and marketing activities.
He holds a Doctor of Medicine degree from Munich’s Ludwig-Maximilians University.